Komori
Soken Chemical & Engineering (4972) · RiskReframed

Risk of Prolonged R&D and Failure to Achieve Commercialization

First written in FY2016. 2 of 4 entries say "Restated". Latest entry: FY2020.

4entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20182016: 120162017: 120172018: 120182019: 020192020: 12020
Same theme, other companies
Risk of R&D investments failing to deliver resultsA theme 120 companies write about · 120 as a headwind · 0 as a tailwind

Soken Chemical & Engineering moved to the "Worse" side of this theme in 2020, 5 years before the typical company in this theme (2025).

The whole theme swung hardest in 2026: 14 of 30 companies on the "Worse" side.

7 other companies' latest entry also says "Reframed".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 120 companies compared. The sentences above are computed from all 120.
Full recordFilings, disclosures and news, newest first
  1. FY2020ReframedAnnual report

    「The Group believes it must continually develop high-value-added products and technologies that meet market and customer needs, and actively conducts both basic and applied research into new products and technologies. However, if it fails to respond appropriately to changes in market and customer needs, this could affect the Group's performance.」

    In addition to the existing risks of prolonged R&D and failure to achieve commercialization, the company explicitly identifies failure to respond to changes in market and customer needs as a risk in developing new products.
  2. FY2018RestatedAnnual report

    「Because the Group's R&D includes basic research, R&D periods may extend over a long term, and there is no guarantee that all R&D projects will be commercialized and contribute to the Group's performance.」

    The company reaffirms the risk of prolonged R&D and the uncertainty that R&D projects may not reach commercialization or contribute to performance.
  3. FY2017RestatedAnnual report

    「Because the Group's R&D includes basic research, R&D periods may extend over a long term, and there is no guarantee that all R&D projects will be commercialized and contribute to the Group's performance.」

    The company reaffirms the risk of prolonged R&D and the uncertainty that R&D projects may not reach commercialization or contribute to performance.
  4. FY2016First statedAnnual report

    「R&D periods may extend over a long term, and there is no guarantee that all R&D projects will be commercialized and contribute to the Group's performance.」

    While stepping up R&D, including basic research, the company explicitly recognizes the uncertainty of realizing results.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Soken Chemical & Engineering yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.